

# Market Announcement

9 December 2020

---

## Cynata Therapeutics Limited (ASX: CYP) – Trading Halt

### Description

The securities of Cynata Therapeutics Limited ('CYP') will be placed in trading halt at the request of CYP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 11 December 2020 or when the announcement is released to the market.

### Issued by

**Melissa Kostopoulos**

Compliance Adviser, Listings Compliance (Melbourne)



9 December 2020

ASX Limited  
Level 4, North Tower Rialto  
525 Collins Street  
Melbourne VIC 3000

Via email: [Melissa.kostopoulos@asx.com.au](mailto:Melissa.kostopoulos@asx.com.au)  
[tradinghaltsmelbourne@asx.com.au](mailto:tradinghaltsmelbourne@asx.com.au)

Dear Melissa

### **TRADING HALT REQUEST**

In accordance with ASX Listing Rule 17.1, Cynata Therapeutics Limited (the **Company**) hereby requests that its securities be placed into an immediate trading halt.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- (a) the trading halt is requested pending an announcement by the Company in relation to a proposed capital raising, to be undertaken by way of an institutional share placement to raise approximately \$15 million and a 1 for 15 pro rata entitlement offer to raise approximately \$5.5 million, at an offer price of \$0.70 per new share;
- (b) the Company requests that the trading halt remain in place until the earlier of the Company making an announcement in relation to the above matters and the opening of trading on Friday, 11 December 2020;
- (c) the Company is not aware of any reason why the trading halt should not be granted; and
- (d) the Company is not aware of any other information necessary to inform the market about the trading halt.

The Company is pleased to announce that Phillip Asset Management Limited as trustee for BioScience Managers Translation Fund 1 has committed to subscribe for \$10 million worth of new shares under the proposed institutional placement, subject to the terms of a subscription agreement dated 9 December 2020.

Authorised by

A handwritten signature in dark ink, appearing to read "Peter Webse", is written over a light blue horizontal line.

**Peter Webse**  
Company Secretary